Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Pastor

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Nature Communications|March 6, 2019
Genome maps across 26 human populations reveal population-specific patterns of structural variationMichal Levy-Sakin, Steven Pastor, Yulia Mostovoy, et al.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Nature Communications|March 6, 2019
Genome maps across 26 human populations reveal population-specific patterns of structural variationMichal Levy-Sakin, Steven Pastor, Yulia Mostovoy, et al.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Pageof 2